"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."
This is HCP only content
To serve the needs of the pharmaceutical industry and users, Terumo and Nemera agreed to cooperate. This to confirm compatibility between PLAJEX™ COP prefillable syringes and the Safe'n'Sound® platform, an add-on passive sharps injury protection device for prefilled syringes (PFS).
In an exciting new era in drug development, the uptake of biopharmaceuticals drives more attention for the development of advanced drug delivery devices. Terumo and Nemera have taken benefit of their polymer science know-how to collaborate and provide the pharma industry with a unique combination of PLAJEX™ polymer-based PFS with Safe'n'Sound®.
PLAJEX™ is a sterile ready-to-fill COP syringe developed by Terumo with a strong focus towards biotherapeutic applications. Key features of PLAJEX™ include:
Safe'n'Sound® is a customizable platform of add-on passive sharps injury protection devices for PFS developed by Nemera. Amidst the key benefits, Safe'n'Sound® offers biopharmaceuticals with:
To establish and confirm compatibility between PLAJEX™ and Safe'n'Sound®, Terumo and Nemera defined a development plan. The performance of this combination has been verified technically through a Design Verification Plan and validated by users through simulated clinical user studies. Preparations are ready for commercial supply: pharmaceutical clients are discussing several projects and plan to launch their drug product into the international market with the PLAJEX™ and Safe'n'Sound® injection system.
For further information, please refer to the whitepaper published in ONdrugDelivery - Prefilled syringe focus, edition N° 73, February 2017.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Nemera is one of the world leaders in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: Parenteral (Safety devices, Autoinjectors and Pens), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free droppers), Pulmonary (pMDIs, DPIs) and Dermal /Transdermal (airless & atmospheric dispensers). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.